Our vision is to transform pulmonary hypertension (PH) into a long-term, manageable condition, so that patients can live a normal life.
Pulmonary hypertension (PH) is raised blood pressure in the arteries delivering blood to the lungs. Heart failure may develop as the condition worsens. The 3-year survival rate is estimated to be around 70%1 even with treatment. There is still much more to be done.
At Janssen, we are spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life.
Building on Actelion's 20-year heritage of pioneering innovation, we are working to ensure that we reach more patients and support them to receive optimal treatment. We continue to take steps towards tackling the diagnosis gap and we are working to find new treatments.
Strange G, et al. Survival of idiopathic pulmonary arterial hypertension patients in the modern era in Australia and New Zealand. Heart Lung Circ 2018; 27(11):1368-1375.